Current perspectives in the management of sepsis and septic shock

被引:2
作者
Chiscano-Camon, Luis [1 ,2 ,3 ]
Ruiz-Sanmartin, Adolf [1 ,2 ]
Bajana, Ivan [1 ,2 ]
Bastidas, Juliana [1 ,2 ]
Lopez-Martinez, Rocio [4 ]
Franco-Jarava, Clara [4 ]
Gonzalez, Juan Jose [5 ]
Larrosa, Nieves [5 ]
Riera, Jordi [1 ,2 ]
Nuvials-Casals, Xavier [1 ,2 ]
Ruiz-Rodriguez, Juan Carlos [1 ,2 ,3 ]
Ferrer, Ricard [1 ,2 ,3 ]
机构
[1] Vall dHebron Barcelona Hosp Campus, Intens Care Dept, Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Barcelona Hosp Campus, Vall dHebron Res Inst VHIR, Shock Organ Dysfunct & Resuscitat Res Grp, Barcelona, Spain
[3] Univ Autonoma Barcelona, Dept Med, Barcelona, Spain
[4] Vall dHebron Barcelona Hosp Campus, Immunol Dept, Vall dHebron Hosp Univ, Barcelona, Spain
[5] Vall Dhebron Univ Hosp, Vall Dhebron Barcelona Hosp Campus, Microbiol Dept, Barcelona, Spain
关键词
septic shock; precision medicine; personalized treatment; treatable trait; hemoadsorption; cytokine storm; sepsis phenotypes; MULTIPLE ORGAN FAILURE; ANGIOTENSIN-II; 28-DAY MORTALITY; ASCORBIC-ACID; VITAMIN-C; THERAPY; ADRENOMEDULLIN; HYDROCORTISONE; ACTIVATION; ADULTS;
D O I
10.3389/fmed.2024.1431791
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Within patients with sepsis, there exists significant heterogeneity, and while all patients should receive conventional therapy, there are subgroups of patients who may benefit from specific therapies, often referred to as rescue therapies. Therefore, the identification of these specific patient subgroups is crucial and lays the groundwork for the application of precision medicine based on the development of targeted interventions. Over the years, efforts have been made to categorize sepsis into different subtypes based on clinical characteristics, biomarkers, or underlying mechanisms. For example, sepsis can be stratified into different phenotypes based on the predominant dysregulated host response. These phenotypes can range from hyperinflammatory states to immunosuppressive states and even mixed phenotypes. Each phenotype may require different therapeutic approaches to improve patient outcomes. Rescue strategies for septic shock may encompass various interventions, such as immunomodulatory therapies, extracorporeal support (e.g., ECMO), or therapies targeted at specific molecular or cellular pathways involved in the pathophysiology of sepsis. In recent years, there has been growing interest in precision medicine approaches to sepsis and phenotype identification. Precision medicine aims to tailor treatments to each individual patient based on their unique characteristics and disease mechanisms.
引用
收藏
页数:13
相关论文
共 110 条
  • [41] Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study
    Friesecke, Sigrun
    Stecher, Stephanie-Susanne
    Gross, Stefan
    Felix, Stephan B.
    Nierhaus, Axel
    [J]. JOURNAL OF ARTIFICIAL ORGANS, 2017, 20 (03) : 252 - 259
  • [42] Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study
    Fujimori, Kenji
    Tarasawa, Kunio
    Fushimi, Kiyohide
    [J]. ANNALS OF INTENSIVE CARE, 2021, 11 (01)
  • [43] Renin-angiotensin system revisited
    Fyhrquist, F.
    Saijonmaa, O.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2008, 264 (03) : 224 - 236
  • [44] Mortality Risk Prediction in Abdominal Septic Shock Treated with Polymyxin-B Hemoperfusion: A Retrospective Cohort Study
    Garcia-Ramos, Sergio
    Caamano, Estrela
    Rodriguez Benitez, Patrocinio
    Benito, Pilar
    Calvo, Alberto
    Ramos, Silvia
    Power, Mercedes
    Garutti, Ignacio
    Pineiro, Patricia
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (07):
  • [45] The mechanism of action of the adrenomedullin-binding antibody adrecizumab
    Geven, Christopher
    Pickkers, Peter
    [J]. CRITICAL CARE, 2018, 22
  • [46] Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis
    Geven, Christopher
    Kox, Matthijs
    Pickkers, Peter
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [47] A New Method for Optimizing Sepsis Therapy by Nivolumab and Meropenem Combination: Importance of Early Intervention and CTL Reinvigoration Rate as a Response Marker
    Gillis, Avi
    Ben Yaacov, Anat
    Agur, Zvia
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [48] Hemoadsorption in the critically ill-Final results of the International CytoSorb Registry
    Hawchar, Fatime
    Tomescu, Dana
    Traeger, Karl
    Joskowiak, Dominik
    Kogelmann., Klaus
    Soukup., Jens
    Friesecke, Singrun.
    Jacob, David
    Gummert, Jan
    Faltlhauser, Andreas
    Aucella, Filippo
    van Tellingen, Martijn
    Malbrain, Manu L. N. G.
    Bogdanski, Ralph
    Weiss, Guenter
    Herbrich, Andreas
    Utzolino, Stefan
    Nierhaus, Axel
    Baumann, Andreas
    Hartjes, Andreas
    Henzler, Dietrich
    Grigoryev, Evgeny
    Fritz, Harald
    Bach, Friedhelm
    Schroeder, Stefan
    Weyland, Andreas
    Gottschaldt, Udo
    Menzel, Matthias
    Zachariae, Olivier
    Novak, Radovan
    Berden, Jernej
    Haake, Hendrik
    Quintel, Michael
    Kloesel, Stephan
    Kortgen, Andreas
    Stecher, Stephanie
    Torti, Patricia
    Nestler, Frieder
    Nitsch, Markus
    Olboeter, Detlef
    Muck, Philip
    Findeisen, Michael
    Bitzinger, Diane
    Krassler, Jens
    Benad, Martin
    Schott, Martin
    Schumacher, Ulrike
    Molnar, Zsolt
    Brunkhorst, Frank Martin
    [J]. PLOS ONE, 2022, 17 (10):
  • [49] Discovery of a selective and biologically active low-molecular weight antagonist of human interleukin-1ß
    Hommel, Ulrich
    Hurth, Konstanze
    Rondeau, Jean-Michel
    Vulpetti, Anna
    Ostermeier, Daniela
    Boettcher, Andreas
    Brady, Jacob Peter
    Hediger, Michael
    Lehmann, Sylvie
    Koch, Elke
    Blechschmidt, Anke
    Yamamoto, Rina
    Dottorello, Valentina Tundo
    Haenni-Holzinger, Sandra
    Kaiser, Christian
    Lehr, Philipp
    Lingel, Andreas
    Mureddu, Luca
    Schleberger, Christian
    Blank, Jutta
    Ramage, Paul
    Freuler, Felix
    Eder, Joerg
    Bornancin, Frederic
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [50] Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
    Hotchkiss, Richard S.
    Monneret, Guillaume
    Payen, Didier
    [J]. LANCET INFECTIOUS DISEASES, 2013, 13 (03) : 260 - 268